Stem Cell Research on Proteins Gives New Insights into SchizophreniaPsychiatry AdvisorStem cells in patients with schizophrenia produce new proteins more slowly compared to healthy people, a finding that researchers say may provide new approaches to dr… Continue reading
BioPharma Dive |
USC, Sangamo Scientists Show Improved ZFN Activity in Hematopoietic Stem Cell …
GenomeWeb NEW YORK (GenomeWeb) – Scientists have shown an improved ability to edit genomes in human hematopoietic stem and progenitor cells (HSPCs) using zinc finger nucleases by introducing the enzymes into the cell as mRNA. Scientists led by Paula … Researchers just discovered how to make blood stem cell genome editing a lot …BioPharma Dive |
Xconomy |
Astellas offers $379M buyout for a pioneering stem cell survivor
FierceBiotech Astellas Pharma has stepped up with a $379 million bid for Ocata Therapeutics, a pioneering–and often controversial–stem cell company that has managed to survive a years-long roller coaster ride through the hype, hope and disappointments of the past … With $379M Deal For Ocata, Astellas Buys Stem Cells For Eye DiseasesXconomy Marlborough stem cell pioneer Ocata attracts buyout bid for nearly double its …Boston Business Journal (blog) Astellas Pharma to buy stem cell pioneer OcataTaipei Times Worcester Telegram all 48 news articles » |
EurekAlert (press release) |
Novel stem cell line avoids risk of introducing transplanted tumors
EurekAlert (press release) Human pluripotent stem cells (hPSC) can become any type of cell in the adult body, offering great potential in disease modeling, drug discovery and creating replacement cells for conditions ranging from cardiovascular to Alzheimer’s disease. But that … |
Xconomy |
With $379M Deal For Ocata, Astellas Buys Stem Cells For Eye Diseases
Xconomy Japanese drug firm Astellas Pharma announced late Monday it has agreed to buy Ocata Therapeutics (NASDAQ: OCAT), which is developing regenerative medicines for eye diseases. It’s an all-cash deal worth $379 million, with the Astellas offer of $8.50 a … Astellas Pharma to Acquire Ocata TherapeuticsNew York Times Astellas to Acquire Ocata TherapeuticsMarketWatch |
|
Public policy needed to reduce stem cell tourism, say experts
News-Medical.net The continued marketing and use of experimental stem cell-based interventions inside and outside the United States is problematic and unsustainable, according to a new paper by science policy and bioethics experts at Rice University’s Baker Institute … |